Infliximab-axxq 100 mg
RxNorm 2266524

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2266524 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: infliximab-axxq 100 mg.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCDC
Infliximab-axxq 100 mg
AUI:11809607
View
TMSY
InFLIXimab-axxq 100 mg
AUI:11811003
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCDCPrescribable

Semantic Clinical Drug Component (SCDC):
Infliximab-axxq 100 mg
(Atom ID: 11809607)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
infliximab-axxq 100 MG
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2266524
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
11809607
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCDC
Semantic Clinical Drug Component (Ingredient + Strength)
Source Code
2266524
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN BOSS STRENGTH DENOM UNIT
1
RXN Boss Strength Denom Unit
RXN BOSS STRENGTH DENOM VALUE
1
RXN Boss Strength Denom Value
RXN BOSS STRENGTH NUM UNIT
MG
RXN Boss Strength Num Unit
RXN BOSS STRENGTH NUM VALUE
100
RXN Boss Strength Num Value
RXN IN EXPRESSED FLAG
P
Strength Expressed As Precise Flag
RXN STRENGTH
100 MG
Strength plus unit of SCDC
TMSYPrescribable

Tall Man Lettering Synonym (TMSY):
InFLIXimab-axxq 100 mg
(Atom ID: 11811003)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
inFLIXimab-axxq 100 MG
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2266524
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
11811003
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
TMSY
Tall Man Lettering Synonym (Tall Man Lettering synonym of another TTY, given to distinguish between commonly confused drugs.)
Source Code
2266524
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Infliximab Injection


Infliximab injection products are used to relieve the symptoms of certain autoimmune disorders (conditions in which the immune system attacks healthy parts of the body and causes pain, swelling, and damage) including: rheumatoid arthritis (a condition in which the body attacks its own joints, causing pain, swelling, and loss of function) that is also being treated with methotrexate (Rheumatrex, Trexall), Crohn's disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever) in adults and children 6 years of age or older that has not improved when treated with other medications, ulcerative colitis (condition that causes swelling and sores in the lining of the large intestine) in adults and children 6 years of age or older that has not improved when treated with other medications, ankylosing spondylitis (a condition in which the body attacks the joints of the spine and other areas causing pain and joint damage), plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults when other treatments are less appropriate, and psoriatic arthritis (a condition that causes joint pain and swelling and scales on the skin). Infliximab injection products are in a class of medications called tumor necrosis factor-alpha (TNF-alpha) inhibitors. They work by blocking the action of TNF-alpha, a substance in the body that causes inflammation.
[Learn More]


* Please review the disclaimer below.